These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38367867)

  • 1. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?
    Splendiani E; Besharat ZM; Covre A; Maio M; Di Giacomo AM; Ferretti E
    Pharmacol Ther; 2024 Apr; 256():108613. PubMed ID: 38367867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. uPAR
    Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
    Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers.
    He R; Lu J; Feng J; Lu Z; Shen K; Xu K; Luo H; Yang G; Chi H; Huang S
    Front Immunol; 2024; 15():1435187. PubMed ID: 39026661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy.
    Karlsson MJ; Costa Svedman F; Tebani A; Kotol D; Höiom V; Fagerberg L; Edfors F; Uhlén M; Egyhazi Brage S; Maddalo G
    Cancer Res; 2021 May; 81(9):2545-2555. PubMed ID: 33574091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
    de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
    Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
    Tian J; Quek C
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
    Laino AS; Woods D; Vassallo M; Qian X; Tang H; Wind-Rotolo M; Weber J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives.
    Hossain SM; Carpenter C; Eccles MR
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
    Mao R; Yang F; Zhang T; Li J
    Front Immunol; 2021; 12():756282. PubMed ID: 35003069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Dravillas CE; Coleman SS; Hoyd R; Caryotakis G; Denko L; Chan CHF; Churchman ML; Denko N; Dodd RD; Eljilany I; Hardikar S; Husain M; Ikeguchi AP; Jin N; Ma Q; McCarter MD; Osman AEG; Robinson LA; Singer EA; Tinoco G; Ulrich CM; Zakharia Y; Spakowicz D; Tarhini AA; Tan AC;
    Cancer Res Commun; 2024 Aug; 4(8):1978-1990. PubMed ID: 39015091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
    Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
    Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy toxicity predicted by circulating cytokines.
    Gourd E
    Lancet Oncol; 2018 Dec; 19(12):e676. PubMed ID: 30449658
    [No Abstract]   [Full Text] [Related]  

  • 17. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
    Coleman S; Xie M; Tarhini AA; Tan AC
    Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients.
    Dufau C; Genais M; Mucher E; Jung B; Garcia V; Montfort A; Tosolini M; Clarke CJ; Medin JA; Levade T; Delord JP; Meyer N; Pancaldi V; Andrieu-Abadie N; Ségui B
    Front Immunol; 2024; 15():1421432. PubMed ID: 39136013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
    Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
    JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma.
    Lin W; Lin A; Li Z; Zhou C; Chen C; Chen B; Lyu Q; Zhang J; Luo P
    Biomed Pharmacother; 2020 Nov; 131():110633. PubMed ID: 32892029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.